Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. In this phase II study, 14 patients with measurable metastatic melanoma were scheduled to receive hu14.18-IL2 at 6 mg/m(2)/day as 4...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: Albertini, Mark R., Hank, Jacquelyn A., Gadbaw, Brian, Kostlevy, Jordan, Haldeman, Jennifer, Schalch, Heidi, Gan, Jacek, Kim, KyungMann, Eickhoff, Jens, Gillies, Stephen D., Sondel, Paul M.
Formáid: Artigo
Teanga:Inglês
Foilsithe: Springer-Verlag 2012
Ábhair:
Original Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3502633/
https://ncbi.nlm.nih.gov/pubmed/22678096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1286-5
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla